
## Domenica Ronchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4705308/publications.pdf Version: 2024-02-01



DOMENICA PONCHETTI

#	Article	IF	CITATIONS
1	DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica, 2022, 107, 921-932.	3.5	14
2	In Vitro Silencing of IncRNAs Using LNA GapmeRs. Methods in Molecular Biology, 2021, 2348, 157-166.	0.9	5
3	Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs. Journal of Clinical Medicine, 2021, 10, 1295.	2.4	5
4	Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 2021, 13, 3213.	3.7	16
5	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. Cancers, 2021, 13, 4898.	3.7	8
6	Bioinformatics Pipeline to Analyze IncRNA Arrays. Methods in Molecular Biology, 2021, 2348, 45-53.	0.9	1
7	Dissecting the Biological Relevance and Clinical Impact of IncRNA MIAT in Multiple Myeloma. Cancers, 2021, 13, 5518.	3.7	0
8	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	7.2	80
9	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. Non-coding RNA, 2020, 6, 11.	2.6	11
10	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. Non-coding RNA, 2020, 6, 26.	2.6	27
11	Expression Pattern and Biological Significance of the IncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers, 2020, 12, 782.	3.7	6
12	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 2019, 11, 236.	3.7	35
13	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica, 2019, 104, e72-e76.	3.5	27
14	Long Non-Coding RNAs in Multiple Myeloma. Genes, 2018, 9, 69.	2.4	22
15	A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Scientific Reports, 2018, 8, 6557.	3.3	34
16	<i>IL21R</i> expressing CD14 <sup>+</sup> CD16 <sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	3.5	36
17	Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget, 2017, 8, 60605-60623.	1.8	25
18	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget, 2017, 8, 106527-106537.	1.8	60

Domenica Ronchetti

#	Article	IF	CITATIONS
19	In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. Genes, 2016, 7, 107.	2.4	17
20	Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget, 2016, 7, 14814-14830.	1.8	79
21	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer Journal, 2016, 6, e468-e468.	6.2	47
22	A p53â€Dependent Tumor Suppressor Network Is Induced by Selective miRâ€125aâ€5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology, 2014, 229, 2106-2116.	4.1	86
23	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 264-273.	2.8	10
24	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	1.5	73
25	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	6.2	70
26	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5369-5378.	7.0	91
27	Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis, 2009, 30, 1330-1335.	2.8	99
28	Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Biochemical Pharmacology, 2009, 78, 1139-1147.	4.4	9
29	Integrative highâ€resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes and Cancer, 2009, 48, 521-531.	2.8	60
30	An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Medical Genomics, 2008, 1, 37.	1.5	104
31	Repetitive DNA Hypomethylation in Multiple Myeloma. Blood, 2008, 112, 2703-2703.	1.4	16
32	Relevance ofRas gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematological Oncology, 2007, 25, 6-10.	1.7	8
33	Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. Genes Chromosomes and Cancer, 2007, 46, 226-238.	2.8	62
34	Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia, 2007, 21, 1113-1116.	7.2	45
35	Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma Blood, 2007, 110, 2486-2486.	1.4	0
36	Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles Blood, 2007, 110, 2482-2482.	1.4	0

Domenica Ronchetti

#	Article	IF	CITATIONS
37	Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. British Journal of Haematology, 2005, 131, 214-218.	2.5	24
38	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes and Cancer, 2005, 42, 117-127.	2.8	49
39	Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma. JAMA Otolaryngology, 2004, 130, 303.	1.2	15
40	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. Journal of Laryngology and Otology, 2002, 116, 610-612.	0.8	1
41	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. Laboratory Investigation, 2002, 82, 1327-1334.	3.7	40
42	Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 2001, 20, 3553-3562.	5.9	98
43	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. Blood, 1999, 93, 1330-1337.	1.4	80
44	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. , 1998, 79, 263-268.		46
45	Clinical relevance of p53 and bclâ€2 protein overâ€expression in laryngeal squamousâ€cell carcinoma. International Journal of Cancer, 1998, 79, 263-268.	5.1	2
46	Identification of a Novel Gene,PSD,Adjacent toNFKB2/lyt-10,Which Contains Sec7 and Pleckstrin-Homology Domains. Genomics, 1997, 46, 251-259.	2.9	27
47	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene. Blood, 1997, 90, 4062-4070.	1.4	201
48	Reverse transcriptase/polymerase chain reaction followâ€up and minimal residual disease detection in t(1;19)â€positive acute lymphoblastic leukaemia. British Journal of Haematology, 1996, 92, 653-658.	2.5	24